PAP
SGMT icon

Persistent Asset Partners’s Sagimet Biosciences SGMT Stock Holding History

Persistent Asset Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,597
Closed -$34.5K – 231
2025
Q1 		$34.5K Buy
+10,597
New +$44.4K 0.03% 141

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

Persistent Asset Partners's SGMT Position: Q2 2025 in Review

Persistent Asset Partners sold out of Sagimet Biosciences (SGMT) in Q2 2025, closing a stake of 10,597 shares — an estimated $34.5K sold.

Persistent Asset Partners first reported a position in SGMT in Q1 2025 and held it in 1 quarter. The position peaked at $34.5K in Q1 2025. 67 funds tracked by Wall St. Rank hold SGMT as of Q2 2025.

  • Persistent Asset Partners reported no remaining Sagimet Biosciences position as of Q2 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 10,597 Sagimet Biosciences shares in Q2 2025, an estimated $34.5K.
  • Persistent Asset Partners first reported a position in Sagimet Biosciences in Q1 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Sagimet Biosciences position peaked at $34.5K in Q1 2025.
  • 67 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2025.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.